Ophthalmology Breaking News

👁 Stay Ahead in Ophthalmology with OBN Join a community of over +53,000 professionals from medical experts to key opinion leaders. 📌 Don't miss out on the latest advancements and technologies. 📌 Get weekly latest updates every Friday straight into your inbox. 📌 Access exclusive articles and interviews. Don't miss out on the opportunity to stay informed and connected, subscribe now and receive free updates every week. https://lnkd.in/dbN2-tdZ #Ophthalmology #Newsletter #Healthcare #MedicalUpdates #OphthalmologyNews #OBN

🔬 Stem Cell Transplant Shows Promise for Wet AMD Treatment 👁️ A new clinical study has confirmed the safety of a stem cell-based therapy for wet age-related macular degeneration (AMD), offering hope for patients with advanced vision loss. 🔑 Key Findings: ✅ Complete removal of abnormal blood vessels improved retinal structure and allowed transplanted stem cells to repair damaged tissue. ✅ Patients showed stable or improved vision over a 12-month follow-up period. ✅ Partial removal of blood vessels led to persistent inflammation, preventing full retinal regeneration. 🔗 Read more here: https://lnkd.in/gxeUihfJ #AMD #VisionLoss #GeneTherapy #Innovation #Ophthalmology #EyeHealth

🏆 Professor Michael Belkin Honored with Lifetime Achievement Award at MIXiii 2025 👁️ Renowned ophthalmic innovator Professor Michael Belkin has been awarded the Lifetime Achievement Award at MIXiii 2025, recognizing his groundbreaking contributions to ophthalmic innovation and medical technology. 🔹 A Legacy of Innovation: ✅ Inventor of Belkin Vision technology, acquired by Alcon in a deal worth up to $466 million ✅ Leading NurExone Biologic’s ophthalmology research, advancing optic nerve regeneration for glaucoma ✅ Dedicated to developing neuroprotective treatments for vision loss 🎙️ Industry Recognition "Professor Belkin’s lifelong dedication to ophthalmology continues to inspire and drive progress in the field," said Dr. Lior Shaltiel, CEO of NurExone Biologic. 👏 Join us in celebrating Professor Belkin’s achievements and the future of vision science! 🔗 Read more here: https://lnkd.in/gvYv9TrS #EyeHealth #Innovation #Congress #Ophthalmology #VisionScience

🔬 RetinalGeniX Technologies, Inc. Tests Remote Ocular Monitoring System for 24/7 Eye Health Screening 👁️ RetinalGenix Technologies has begun testing its first prototype of a real-time remote ocular monitoring system, designed to enhance early detection and screening for vision-threatening conditions. 🔑 Key Features: ✅ 24/7 remote monitoring from virtually any location ✅ No technician or pupil dilation required for a 40-degree field of vision ✅ Instant image access for remote physicians to support immediate assessments ✅ Planned deployment in pharmacies, hospitals, urgent care centers, and senior living facilities 🔗 Read more here: https://lnkd.in/dKDVbQ77 #EyeHealth #Innovation #Diagnostics #Ophthalmology #VisionCare

🚀 Perceive Pharma Secures $15M to Advance Neuroprotective Glaucoma Therapies  Perceive Pharma has raised $15 million in Series A funding to accelerate the development of neuroprotective treatments for glaucoma and vision loss. Investors include Deerfield Management, Johnson & Johnson, Braidwell LP, GV, the Retinal Degeneration Fund, and Catalio Capital Management. 🔹 Why This Matters: ✅ Traditional glaucoma treatments focus on lowering intraocular pressure (IOP), but nearly half of patients continue to lose vision despite normal IOP levels. ✅ Perceive’s lead candidate, PBI-671, aims to protect retinal cells, addressing an urgent unmet need in ophthalmology. ✅ The funding will support preclinical and clinical research to develop transformative, sight-saving therapies. 🔗 Read more here: https://lnkd.in/d-r_2c-J #Glaucoma #VisionLoss #Innovation #Ophthalmology #Neuroprotection

🚀 Zeiss Visumax 800 with SMILE Pro Approved in China  ZEISS Group has received NMPA approval in China for the Visumax 800 femtosecond laser with SMILE Pro software, expanding access to advanced laser vision correction across Asia. This next-generation system enhances precision, efficiency, and patient outcomes for myopia and astigmatism correction. 🔑 Key Features: ✅ Faster procedure time – Lenticule creation in under 10 seconds ✅ Enhanced surgical workflow – CentraLign, OcuLign, and VISULYZE for improved accuracy ✅ Minimized patient stress with a high-speed 1MHz pulse repetition rate 🔗 Read more here: https://lnkd.in/dPam8sui #Launch #Myopia #Innovation #LaserVisionCorrection #Ophthalmology #Zeiss

🚀 FDA Fast Tracks Opus Genetics’ Phentolamine as Phase 3 Trials Advance  Opus Genetics has received FDA Fast Track designation for phentolamine ophthalmic solution 0.75%, a potential treatment for night vision impairment following keratorefractive surgery. Meanwhile, enrollment has been completed for the VEGA-3 Phase 3 trial in presbyopia, and the LYNX-2 Phase 3 trial for low-light vision disturbances is nearing full enrollment. 🔑 Key Developments: ✅ VEGA-3 Phase 3 Trial (Presbyopia): Fully enrolled, evaluating near vision improvement ✅ LYNX-2 Phase 3 Trial (Night Vision Impairment): Over 95% enrolled, assessing low-light vision enhancement ✅ FDA Fast Track Designation enables priority review and accelerates regulatory pathways 🔗 Read more here: https://lnkd.in/gsxCX7p2 #FDA #Presbyopia #ClinicalTrial #Innovation #Ophthalmology #VisionHealth

🧠👁️ New Research Links Breathing to Pupil Size and Vision A groundbreaking study from Karolinska Institutet reveals that breathing directly influences pupil size, adding a new dimension to how vision is regulated. Published in the Journal of Physiology, the research shows that the pupil is smallest during inhalation and largest during exhalation, a previously unknown mechanism that may impact visual perception and neurological function. 🔑 Key Findings: ✅ Pupil size changes independently of light, focus, or cognitive effort ✅ The effect remains consistent across different breathing speeds and conditions ✅ Controlled by the brainstem, suggesting a fundamental biological function ✅ May influence how we process visual details and detect faint objects 🔗 Read more here: https://lnkd.in/d2p3c-Ha #EyeHealth #ScientificResearch #Innovation #VisionScience #Ophthalmology

🚨 FDA Grants RMAT Designation to Luxa’s RPESC-RPE-4W for Dry AMD 🚨 The FDA has awarded Regenerative Medicine Advanced Therapy (RMAT) designation to RPESC-RPE-4W transplantation, a promising cell therapy developed by Luxa Biotechnology LLC for dry age-related macular degeneration (AMD). 🔹 Why This Matters: ✅ Stem cell-based therapy designed to replace lost RPE cells in AMD ✅ RMAT designation accelerates development and regulatory review ✅ Currently in Phase 1/2a clinical trials, showing early potential to restore vision 🔗 Read more here: https://lnkd.in/dSASDct6 #FDA #AMD #GeneTherapy #VisionLoss #Ophthalmology #Innovation

🚨 UK MHRA Approves Aflibercept Biosimilar AHZANTIVE for Retinal Diseases  Formycon AG has received MHRA approval for FYB203 (AHZANTIVE), a biosimilar to aflibercept (Eylea), expanding treatment options for neovascular AMD, diabetic macular edema, retinal vein occlusion, and myopic choroidal neovascularization. 🔑 Key Milestones: ✅ Approved in the UK under the brand name AHZANTIVE ✅ Approved in the EU under the names AHZANTIVE and Baiama ✅ FDA approval granted in June 2024 Formycon is partnering with Teva Pharmaceuticals to commercialize AHZANTIVE, building on their collaboration for FYB201 (biosimilar to ranibizumab, Lucentis). 🔗 Read more here: https://lnkd.in/dyPZ_u9w #EyeHealth #Treatment #VisionLoss #Biosimilars #Ophthalmology